Targeted therapy before surgery for older adults with HER2-positive breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two targeted drugs (trastuzumab and pertuzumab) and a low-dose chemotherapy (vinorelbine) given before surgery to shrink HER2-positive breast tumors in older adults. The goal is to reduce the tumor size to make surgery easier and hopefully improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years of age or older.
- You have HER2-positive breast cancer (a type that grows in response to a protein called HER2).
- Your tumor is larger than 2 cm, or the cancer has spread to lymph nodes under the arm.
- You have not had any prior treatment for this breast cancer, such as chemo, hormone therapy, or HER2-targeted drugs.
- Your cancer has not spread to distant organs (like the lungs or liver).
- You are generally in good health and able to care for yourself (ECOG 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This study tests whether giving two drugs (SHR-A1811 and pertuzumab) before surgery can shrink HER2-positive breast cancer tumors. It aims to see if this combination improves treatment outcomes for patients with stage II or III disease.
Hear when a new Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.